Entering text into the input field will update the search result below

Johnson & Johnson (JNJ) CEO Joaquin Duato on Q2 2022 Results - Earnings Call Transcript

Jul. 19, 2022 1:27 PM ETJohnson & Johnson (JNJ) Stock
SA Transcripts profile picture
SA Transcripts

Johnson & Johnson (NYSE:JNJ) Q2 2022 Earnings Conference Call July 19, 2022 8:30 AM ET

Company Participants

Jessica Moore - Vice President, Investor Relations

Joaquin Duato - Chief Executive Officer

Joe Wolk - Chief Financial Officer

Conference Call Participants

Terence Flynn - Morgan Stanley

Larry Biegelsen - Wells Fargo

Chris Schott - JPMorgan

Joanne Wuensch - Citi

Louise Chen - Cantor Fitzgerald

Josh Jennings - Cowen

Chris Shibutani - Goldman Sachs

David Risinger - SVB Securities


Good morning and welcome to Johnson & Johnson’s Second Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference call over to Johnson & Johnson. You may begin.

Jessica Moore

Please note that today’s meeting may include forward-looking statements relating to, among other things, the company’s future financial performance, product development, market position and business strategy and the anticipated separation of the company’s consumer health business. You are cautioned not to rely on these statements, which are based on current expectations of future events using the information available as of today’s date and are subject to certain risks and uncertainties that may cause the company’s actual results to differ materially from those projected. In particular, there is significant uncertainty about the duration and contemplated impact of the COVID-19 pandemic. A further description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2021 Form 10-K, which is available at investor.jnj.com and on the SEC’s website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. These slides acknowledge those relationships.

Joaquin Duato

Good morning, everyone. This is Joaquin Duato, Chief Executive Officer of Johnson & Johnson. Thanks for joining us today. I am accompanied by Joe Wolk and Jessica Moore and we have the privilege to share

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About JNJ

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on JNJ

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.